Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Account Payables
Amounts the company owes suppliers for goods and services received.
Ovid Therapeutics Inc.NASDAQ: OVID
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 355.2% from a year ago
Account payables stood at $8.88M at the end of Q1 FY2026, up 355.2% from a year earlier and up 353.8% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.
Context
- Account payables amounted to 3.9% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +355.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.96M USD
- Year-over-year change
- -38.7%
- 4-year CAGR
- -27.6%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.96M | -38.7% |
| FY2024 | 2024-12-31 | 3.19M | -13.8% |
| FY2023 | 2023-12-31 | 3.7M | +89.6% |
| FY2022 | 2022-12-31 | 1.95M | -72.6% |
| FY2021 | 2021-12-31 | 7.13M | — |
Account Payables vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's Mar 2026 account payables of $8.88M is the 5th highest of the 11 companies compared; the peer median is $5.76M.
- Its year-over-year change of +355.2% is the highest of 11, against a peer median of -4.1%.
- Account payables amounts to 3.9% of total assets for OVID, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $42M | -11.5% | -10.5% | 3.2% | |
| Mar 2026 | $19.06M | +32.8% | -2.5% | 3.3% | |
| Mar 2026 | $16.66M | -17.9% | -15.4% | 6.8% | |
| Jun 2026 | $9.16M | +18.8% | -16.9% | 1.9% | |
| Mar 2026 | $8.88M | +355.2% | +0.1% | 3.9% | |
| Mar 2026 | $6.84M | +212.9% | +86.1% | 1.5% | |
| Mar 2026 | $4.69M | +53.0% | +46.2% | 1.8% | |
| Mar 2026 | $4.07M | -18.9% | +63.3% | 2.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $3.34M | -72.2% | +21.9% | 1.3% |
| Mar 2026 | $2.72M | +3.4% | +25.0% | 1.2% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding OVID) | $5.76M | -4.1% | +21.9% | 1.9% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 187.8M | 44.87M | 27.04M | 26.3M | 13.15M |
| Short-term Investments | 0 | 84.13M | 78.79M | 26.77M | 56.48M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.68M | 1 | 1K | 0 | 20.81M |
| Total Current Assets | 190.48M | 131.38M | 109.6M | 55.94M | 90.45M |
| Property, Plant & Equipment (Net) | 242.76K | 16.07M | 14.66M | 13.23M | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 164K | 222.1K | 200K | 92K | 0 |
| Long-term Investments | 3.56M | 5.62M | 17.63M | 20.97M | 64.7M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 96.13K | 1.97M | 1.94M | 1.93M | (4.22M) |
| Total Non-current Assets | 4.07M | 23.89M | 34.43M | 36.23M | 60.49M |
| Total Assets | 194.54M | 155.27M | 144.03M | 92.17M | 150.93M |
| Account Payables | 7.13M | 1.95M | 3.7M | 3.19M | 1.96M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.91M | 0 | 0 | 1K | 0 |
| Total Current Liabilities | 14.8M | 6.99M | 11.47M | 10.52M | 8.29M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 1 | 30M | 0 | 0 |
| Total Non-current Liabilities | 0 | 16M | 44.76M | 13.42M | 11.99M |
| Total Liabilities | 14.8M | 22.99M | 56.23M | 23.94M | 20.27M |
| Common Stock | 70.36K | 70.47K | 71K | 71K | 130K |
| Retained Earnings | (171.36M) | (225.53M) | (277.87M) | (304.3M) | (321.71M) |
| Accumulated OCI | 0 | (42.19K) | 0 | (35K) | (202K) |
| Other Stockholders Equity | 0 | (1) | 0 | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 179.75M | 132.27M | 87.8M | 68.23M | 130.66M |
| Total Debt | 0 | 16.54M | 16M | 14.76M | 13.42M |
| Net Debt | (187.8M) | (28.33M) | (11.04M) | (11.55M) | 266K |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.